Even though some experimental studies have suggested the pathogenic role of anti-GAD antibodies (Stagg et al., 2010; Chang et al., 2013; Hansen et al., 2013; Graus et al., 2020), this remains controversial due to the intracellular location of the GAD enzyme, and the poor correlation between the clinical manifestations and anti-GAD antibody titers, especially in stiff-person syndrome. The gene discussed is GAD1; the disease is stiff-person syndrome.